Most of the business headlines you see relate to only a relatively small number of stocks. This could be a version of the famous Pareto principle at work: 80% of outcomes come from 20% of causes.

But while a select group of stocks receives most of the limelight, there are potentially big winners that aren’t usually at the center of investors’ attention. Here are three under-the-radar stocks that are great buys right now.

1. Ball

Ball (NYSE:BLL) is a 140-year-old company once best known for making jars — which probably doesn’t sound like the most exciting business. Today, Ball still makes jars. However, it focuses more heavily on making aluminum beverage cans. The company even has an aerospace division that works on military and space exploration projects. Now we’re getting to some excitement, right?

I suspect that investors will get excited about Ball’s performance. Between 2000 and 2020, Ball’s stock price achieved a compound annual growth rate of over 18%. That’s more than three times greater than the S&P 500 index‘s growth rate during the same period. Last year, Ball’s shares soared 44% compared to the S&P 500‘s 16% gain.

The company should be able to keep its tremendous momentum going. Consumers and beverage companies are increasingly looking for sustainable alternatives to single-use plastic beverage containers. Ball’s aluminum cans are perfect solutions. In fact, roughly 75% of all the aluminum ever produced is still in use today.

Ball’s growth will also be boosted by the rising adoption of new product categories, including energy drinks, hard seltzers, and canned water. And while its aerospace unit remains a relatively small part of the company’s overall business, the sales backlog for this unit is at an all-time high.

2. DermTech

DermTech (NASDAQ:DMTK) takes the idea of skin in the game to an entirely different level. The company developed a noninvasive genomics test for diagnosing skin cancer. In the past, dermatologists had to conduct a visual assessment, then cut out part of the skin to get a biopsy to be analyzed. With DermTech’s approach, an adhesive patch is applied to the suspect area, removed, then sent to a lab. Genomic analysis is typically available with 72 hours.

Sound like a great idea? DermTech thinks so. So do several major payers that have agreed to reimburse for the company’s noninvasive genomic test for melanoma. Investors like DermTech’s prospects: The healthcare stock skyrocketed 162% last year.

The company’s potential market is…

Continue reading at THE MOTLEY FOOL